LivaNova PLC Ordinary Shares

LIVN

LivaNova PLC is a global medical device company specializing in innovative solutions for cardiac and neurological conditions. Founded in 2018 through the merger of Sorin Group and Cyberonics, the company focuses on developing and manufacturing devices for cardiac surgery, neuromodulation, and neurocritical care, aiming to improve patient outcomes and quality of life.

$80.70 -1.09 (-1.33%)
🚫 LivaNova PLC Ordinary Shares does not pay dividends

Company News

Brain Implants Market Size to Reach USD 18.39 Billion by 2035, Growing at 9.99% CAGR | SNS Insider
GlobeNewswire Inc. • Sns Insider • June 27, 2026

The global brain implants market, valued at USD 7.10 billion in 2025, is projected to reach USD 18.39 billion by 2035, growing at a CAGR of 9.99%. Growth is driven by rising prevalence of neurological disorders and increasing adoption of deep brain stimulation, neuromodulation systems, and brain-computer interfaces. North America leads the market...

Global Perfusion Systems Market to Register Incremental Growth at a CAGR of ~5% by 2034 | DelveInsight
GlobeNewswire Inc. • Delveinsight • April 23, 2026

The global perfusion systems market is projected to grow from USD 1.5 billion in 2025 to USD 2.4 billion by 2034 at a CAGR of ~5%, driven by increasing cardiovascular disorders, rising organ transplantation procedures, technological innovations, and an aging population. North America leads the market with 41% share. Recent FDA clearances for adva...

MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value
Benzinga • Equity Insider • March 27, 2026

The healthcare sector is shifting toward outpatient clinics and ambulatory services, with AI-powered diagnostics and remote care technologies gaining significant traction. Multiple medtech companies are advancing innovative solutions: VentriPoint Diagnostics is expanding cardiac imaging to remote communities via partnership with First Light Healt...

Global Neuromodulation Devices Market Anticipating Remarkable Growth at a CAGR of ~9% by 2032 | DelveInsight
GlobeNewswire Inc. • Delveinsight • February 23, 2026

The global neuromodulation devices market is projected to grow from USD 7.8 billion in 2024 to USD 16.1 billion by 2032, driven by increasing prevalence of chronic neurological conditions, technological innovations, and supportive regulatory frameworks. North America leads with 55% market share, while Asia-Pacific emerges as the fastest-growing r...

From Humanoid Robots to AI Seating: VivaNova Debuts "Active Health" Tech at imm cologne 2026
GlobeNewswire Inc. • Not Specified • January 26, 2026

VivaNova, backed by Lumos Robotics, officially launched its Viva Series of active ergonomic chairs at imm cologne 2026 and announced the Nova Series—the world's first AI-powered smart chair coming in June 2026. The brand integrates humanoid robot technology into furniture, featuring intelligent motion systems, sensory capabilities, and adaptive...

Related Companies